Eciruciclib - Beta Pharma
Alternative Names: BPI-1178Latest Information Update: 16 Sep 2025
At a glance
- Originator Beta Pharma
- Class Antineoplastics; Indazoles; Pyrimidines; Small molecules
- Mechanism of Action Cyclin-dependent kinase 4 inhibitors; Cyclin-dependent kinase 6 inhibitors
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Phase I/II Breast cancer; Solid tumours
Most Recent Events
- 30 May 2025 Adverse event data from a phase I/II trial in Breast cancer presented at the 61st Annual Meeting of the American Society of Clinical Oncology (ASCO-2025)
- 16 Apr 2024 Beta Pharma in collaboration with National Cancer Center plans a phase I trial for Non-small cell lung cancer (Combination therapy, Late-stage disease, Metastatic disease) (PO) (NCT06362980)
- 28 Mar 2024 No recent reports of development identified for preclinical development in Solid-tumours in USA (PO)